$NBIO News February 23, 2022 The Agreement grants
Post# of 47026
![](/assets/46931549/no_avatar_available_thumb.jpg)
The Agreement grants to BioRay exclusive rights to commercialize Nascent's monoclonal antibody, Pritumumab, in international markets, excluding North America and Central America. Under terms of the Agreement, Nascent will receive a total of USD $5,000,000 to be paid out at various stipulated milestones. The initial payment of USD $1,000,000 was received by Nascent on April 20, 2021.
Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical https://finance.yahoo.com/news/nascent-biotec...00418.html
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)